Vanguard Personalized Indexing Management’s Takeda Pharmaceutical TAK Stock Holding History

Vanguard Personalized Indexing Management’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.04M	Sell	127,525 -4,564	-3%	-$75.5K	0.02%	631
2026 Q1	$2.45M	Sell	132,089 -3,308	-2%	-$58.1K	0.02%	538
2025 Q4	$2.11M	Sell	135,397 -39,700	-23%	-$568K	0.02%	574
2025 Q3	$2.56M	Sell	175,097 -27,215	-13%	-$404K	0.03%	502
2025 Q2	$3.13M	Buy	202,312 +45,959	+29%	+$679K	0.04%	428
2025 Q1	$2.32M	Buy	156,353 +55,729	+55%	+$781K	0.03%	442
2024 Q4	$1.33M	Buy	100,624 +24,495	+32%	+$336K	0.02%	638
2024 Q3	$1.08M	Buy	76,129 +5,961	+8%	+$84.6K	0.02%	728
2024 Q2	$906K	Sell	70,168 -22,911	-25%	-$303K	0.02%	723
2024 Q1	$1.29M	Buy	93,079 +28,466	+44%	+$414K	0.03%	538
2023 Q4	$922K	Buy	64,613 +9,102	+16%	+$129K	0.02%	694
2023 Q3	$859K	Sell	55,511 -8,261	-13%	-$128K	0.03%	640
2023 Q2	$1M	Buy	63,772 +3,844	+6%	+$63K	0.03%	569
2023 Q1	$989K	Buy	59,928 +24,965	+71%	+$398K	0.03%	538
2022 Q4	$545K	Sell	34,963 -17,229	-33%	-$241K	0.02%	773
2022 Q3	$677K	Buy	52,192 +10,006	+24%	+$139K	0.03%	658
2022 Q2	$592K	Buy	42,186 +9,373	+29%	+$134K	0.03%	734
2022 Q1	$470K	Buy	32,813 +16,170	+97%	+$237K	0.02%	857
2021 Q4	$227K	Buy	16,643 +13	+0.1%	+$182	0.01%	957
2021 Q3	$272K	Buy	16,630 +1,672	+11%	+$28.1K	0.02%	799
2021 Q2	$252K	Sell	14,958 -2,488	-14%	-$42.4K	0.03%	805
2021 Q1	$319K	Sell	17,446 -2,082	-11%	-$37.5K	0.05%	480
2020 Q4	$355K	Sell	19,528 -1,268	-6%	-$22.2K	0.08%	304
2020 Q3	$371K	Buy	20,796 +3,323	+19%	+$60.5K	0.1%	233
2020 Q2	$313K	Buy	+17,473	New	+$314K	0.14%	180

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Vanguard Personalized Indexing Management's TAK Position: Q2 2026 in Review

Vanguard Personalized Indexing Management reduced its Takeda Pharmaceutical (TAK) stake by 3.5% in Q2 2026, selling an estimated $75.5K and leaving 127,525 shares worth $2.04M. The position accounts for 0.02% of the portfolio, ranked #631.

Vanguard Personalized Indexing Management first reported a position in TAK in Q2 2020 and has held it in 25 quarters since. The position peaked at $3.13M in Q2 2025. 376 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

Vanguard Personalized Indexing Management held 127,525 shares of Takeda Pharmaceutical worth $2.04M as of Q2 2026.
Vanguard Personalized Indexing Management sold 4,564 Takeda Pharmaceutical shares in Q2 2026, an estimated $75.5K.
Takeda Pharmaceutical made up 0.02% of Vanguard Personalized Indexing Management's portfolio in Q2 2026, its #631 holding.
Vanguard Personalized Indexing Management first reported a position in Takeda Pharmaceutical in Q2 2020 and has held it in 25 quarters since.
Vanguard Personalized Indexing Management's Takeda Pharmaceutical position peaked at $3.13M in Q2 2025.
376 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Vanguard Personalized Indexing Management's 13F filing for Q2 2026, filed 11 Aug 2026.